MedTrace Logo

A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.

NCT07230483 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 246

Last updated 2025-11-17

No results posted yet for this study

Summary

This is an Open-label ,Multicenter Study to evaluate Long-Term Safety and Efficacy of CM512 in patients with Atopic Dermatitis who have completed treatment in parent CM512 Study.

Conditions

  • Atopic Dermatitis (AD)

Interventions

BIOLOGICAL

CM512

CM512 subcutaneous injection

Sponsors & Collaborators

  • Keymed Biosciences Co.Ltd

    lead INDUSTRY

Principal Investigators

  • Jianzhong Zhang · Peking University People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-31
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07230483 on ClinicalTrials.gov